NOVAVAX COMPLETES ESTRASORB PARTNERSHIP

Novavax, Inc. (Nasdaq: NVAX) announced today that it has entered into a definitive license and supply agreement on ESTRASORB(R) (estradiol topical emulsion) with Esprit Pharma, a private specialty pharmaceutical company based in East Brunswick,

NJ. Under the License Agreement, Esprit Pharma will obtain exclusive rights to market ESTRASORB in North America. Novavax will continue to manufacture ESTRASORB in its state-of-the-art pharmaceutical plant in Philadelphia.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/10-18-2005/0004172174&EDATE=)